Competitor Landscape: Lupus
Powered by ![]()
All the vital news, analysis, and commentary curated by our industry experts.
Executive Summary: Contains analysis of key market events that have occurred during the previous month and which have impacted Sociable Pharma’s view of the disease landscape
Landscape Updates: ‘Order of Entry’ analysis, detailing timeline forecasts for each drug in Phase II development or higher; Timeline forecasts for each approved product’s lifecycle management initiatives; ‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies
Pipeline Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Approved Product Landscape: An overview of pipeline candidates, containing snapshots of current development status; Expected drug-specific events & milestones until YE 2019
Scope
The briefing is based on Sociable Pharma’s analysis of clinical trial data from company announcements (press releases, earnings calls) and clinical trial databases (clinicaltrials.gov)
Sociable Pharma applies disease & drug specific assumptions in order to forecast US & EU approvals for drugs in Phase II development, or higher – these are outlined in the report Appendix
Forecasts are presented in pipeline forecast figures & detailed tables
‘Market Entry’ & ‘Direction of Travel’ positioning analysis for pipeline & currently approved therapies is also provided
Key Highlights
Registration of a Phase III AURORA2 long-term extension study indicates efforts by Aurinia to gather additional safety data for voclosporin
GSK is currently the only company conducting pediatric SLE trials, which could provide a significant point of differentiation for belimumab vs. novel competitors, if successful
Inclusion of SRI-4 as a primary endpoint as opposed to SLEDAI-2K (primary endpoint used in baricitinib’s Phase II SLE trial) is in line with competitors such as belimumab, and could allow physicians to draw indirect comparisons between therapies even in the absence of H2H trials
Reasons to Buy
Provides details on forecast US & EU approvals for pipeline drugs in Phase II development or higher
Includes potential positioning strategies that companies may adopt for their novel assets once they are approved & launched in the market
Reviews ongoing lifecycle management strategies for existing players in the market
A detailed methodology allows you to understand the forecast assumptions made, enabling cross comparison with your own internal forecasts
Ablynx
ACEA Biosciences
Amgen
Anthera
Apellis Pharmaceuticals
Astellas
AstraZeneca
Aurinia Pharma
Baxalta
Biogen
Biogen
Biotest
BMS
Boehringer Ingelheim
Boston Pharmaceuticals
Celgene
Chi-Med
Corbus Pharma
Corestem
EMD Serono
Galapagos
Genentech
Gilead
GlaxoSmithKline
Idera Pharmaceuticals
Idorsia
Iltoo Pharma
Immunomedics
ImmuPharma
Imperial College London
Innocare Pharma
Invion
Janssen
Kezar Life Sciences
Lilly
MacroGenics
MedImmune LLC
Mitsubishi Tanabe
Nektar Therapeutics
Neovacs
Novartis
Omeros Corporation
Pfizer
Ra Pharmaceuticals
RemeGen
Resolve Therapeutics
Roche
Sanofi
Seattle Genetics
Shire
Takeda
Theramab
UCB
Xencor
XTL Biopharma
Table of Contents
Frequently asked questions
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Related reports
View more Immunology reports